Why Is Continued Vision Loss Still a Problem in Some Patients With Diabetic Retinopathy, Despite Treatment?

Susan B. Bressler; Peter H. Scanlon; Elizabeth Pearce

doi:10.1001/jamaophthalmol.2022.0135

Why Is Continued Vision Loss Still a Problem in Some Patients With Diabetic Retinopathy, Despite Treatment?

Susan B. Bressler, Peter H. Scanlon, Elizabeth Pearce

School of Medicine

Research output: Contribution to journal › Comment/debate › peer-review

Original language	English (US)
Pages (from-to)	308-309
Number of pages	2
Journal	JAMA ophthalmology
Volume	140
Issue number	4
DOIs	https://doi.org/10.1001/jamaophthalmol.2022.0135
State	Published - Apr 2022

ASJC Scopus subject areas

Ophthalmology

Access to Document

10.1001/jamaophthalmol.2022.0135

Cite this

@article{15d0f605ab54432fa77b77cd6d34b635,

title = "Why Is Continued Vision Loss Still a Problem in Some Patients With Diabetic Retinopathy, Despite Treatment?",

author = "Bressler, {Susan B.} and Scanlon, {Peter H.} and Elizabeth Pearce",

note = "Funding Information: reports grants from Boehringer Ingelheim, Biocon, Biogen, Genentech, Roche, Notal Inc, Novartis, Bayer, Regeneron, EyePoint Pharmaceuticals, Merck, and Mylan paid to Johns Hopkins University and personal fees from Amgen for data monitoring committee participation. Dr Scanlon reports consulting fees from Boehringer Ingelheim and Bayer and speaker fees from Novartis and Topcon; his research team has had grant support from Boehringer Ingelheim and Bayer. Dr Pearce is an employee of Boehringer Ingelheim. No other disclosures were reported.",

year = "2022",

month = apr,

doi = "10.1001/jamaophthalmol.2022.0135",

language = "English (US)",

volume = "140",

pages = "308--309",

journal = "JAMA ophthalmology",

issn = "2168-6165",